118 related articles for article (PubMed ID: 11466819)
1. Comparison of antibodies to MART-1 and MelanA in fine-needle aspiration samples of metastatic malignant melanoma.
Fetsch PA; Filie AC; Steinberg SM; Abati A
Diagn Cytopathol; 2001 Jul; 25(1):78-9. PubMed ID: 11466819
[No Abstract] [Full Text] [Related]
2. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.
Fetsch PA; Marincola FM; Filie A; Hijazi YM; Kleiner DE; Abati A
Cancer; 1999 Feb; 87(1):37-42. PubMed ID: 10096358
[TBL] [Abstract][Full Text] [Related]
3. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.
Kawakami Y; Battles JK; Kobayashi T; Ennis W; Wang X; Tupesis JP; Marincola FM; Robbins PF; Hearing VJ; Gonda MA; Rosenberg SA
J Immunol Methods; 1997 Mar; 202(1):13-25. PubMed ID: 9075767
[TBL] [Abstract][Full Text] [Related]
4. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
[TBL] [Abstract][Full Text] [Related]
5. Immune selection after antigen-specific immunotherapy of melanoma.
Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
[TBL] [Abstract][Full Text] [Related]
6. Analysis of hybridoma-exchange antibodies.
Lloyd KO; Albino A; Houghton A
Hybridoma; 1982; 1(4):461-3. PubMed ID: 6208140
[No Abstract] [Full Text] [Related]
7. Analysis of soluble melanoma cell membrane antigens in metastatic cells of various organs and further studies of antigens present in primary melanoma.
Hollinshead AC
Cancer; 1975 Oct; 36(4):1282-8. PubMed ID: 51680
[TBL] [Abstract][Full Text] [Related]
8. Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look.
Fetsch PA; Steinberg SM; Riker AI; Marincola FM; Abati A
Cancer; 2001 Dec; 93(6):409-14. PubMed ID: 11748581
[TBL] [Abstract][Full Text] [Related]
9. Fine needle aspiration biopsy of metastatic malignant melanoma with "rhabdoid" features. Frequency, cytologic features, pitfalls and ancillary studies.
Slagel DD; Raab SS; Silverman JF
Acta Cytol; 1997; 41(5):1426-30. PubMed ID: 9334131
[TBL] [Abstract][Full Text] [Related]
10. The new melanoma markers: MART-1 and Melan-A (the NIH experience).
Fetsch PA; Marincola FM; Abati A
Am J Surg Pathol; 1999 May; 23(5):607-10. PubMed ID: 10328095
[No Abstract] [Full Text] [Related]
11. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
12. Melanoma metastatic to the breast: utility of fine needle aspiration and immunohistochemistry.
Filie AC; Simsir A; Fetsch P; Abati A
Acta Cytol; 2002; 46(1):13-8. PubMed ID: 11843553
[TBL] [Abstract][Full Text] [Related]
13. Workshop on monoclonal antibodies to human melanoma-associated antigens: findings of the Seattle group.
Hellström I; Brown JP; Hellström KE
Hybridoma; 1982; 1(4):399-402. PubMed ID: 6208136
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the binding characteristics of monoclonal antimelanoma antibodies.
Herlyn M; Steplewski Z; Atkinson BF; Ernst CS; Koprowski H
Hybridoma; 1982; 1(4):403-11. PubMed ID: 6765323
[TBL] [Abstract][Full Text] [Related]
15. Tissue specificity of anti melanoma monoclonal antibodies analyzed on cell lines.
Johnson JP; Riethmüller G
Hybridoma; 1982; 1(4):381-5. PubMed ID: 6208134
[TBL] [Abstract][Full Text] [Related]
16. [Immunological analysis of melanoma-specific antigen].
Wakabayashi S; Okamoto S
Nihon Hifuka Gakkai Zasshi; 1985 Oct; 95(11):1145-51. PubMed ID: 3879298
[No Abstract] [Full Text] [Related]
17. Reactivity spectrum of 30 monoclonal antimelanoma antibodies to a panel of 28 melanoma and control cell lines.
Carrel S; Schreyer M; Schmidt-Kessen A; Mach JP
Hybridoma; 1982; 1(4):387-97. PubMed ID: 6208135
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma.
Catchpole B; Gould SM; Kellett-Gregory LM; Dobson JM
J Small Anim Pract; 2002 Oct; 43(10):464-467. PubMed ID: 12400646
[TBL] [Abstract][Full Text] [Related]
19. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
[TBL] [Abstract][Full Text] [Related]
20. Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97.
Casellas P; Brown JP; Gros O; Gros P; Hellström I; Jansen FK; Poncelet P; Roncucci R; Vidal H; Hellström KE
Int J Cancer; 1982 Oct; 30(4):437-43. PubMed ID: 7141740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
